Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | PPARG | P37231 | 1/20 | 0.78 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.78 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.49 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.48 |
| ▸ | CLIC1 | O00299 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17917294 | 0.93 | PTGS2 (0.85) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL6036626 | 0.91 | PTGS2 (0.82) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL16746714 | 0.90 | PTGS2 (0.65) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29475008 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL29377334 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL4479 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| Lumiracoxib SCHEMBL27680523 | 0.86 | PTGS2 (0.98) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL1031330 | 0.85 | PTGS2 (0.73) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL1029096 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1ABCB11PPARGNR1I3 | |
| SCHEMBL1032907 | 0.83 | PTGS2 (0.69) | PTGS2PTGS1ABCB11PPARGNR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960253-A1 | HUMAN MONOCLONAL ANTIBODIES TO ACTIVIN RECEPTOR-LIKE KINASE-1 | Amgen Fremont Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER, INC. | 2009-08-27 | — | — | US | disclosed |
| US-7537762-B2 | Human monoclonal antibodies to activin receptor-like kinase-1 | AMGEN FREMONT, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. | 2009-04-30 | — | — | US | disclosed |
| US-20070065444-A1 | Human monoclonal antibodies to activin receptor-like kinase-1 | AMGEN FREMONT INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111805-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNB1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNY | PTGS2 3711/4885PTGS1 2642/4885ABCB11 123/4885 |
| US-20090215742-A1 | AMIDE RESORCINOL COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | PTGS2 2000/4885PTGS1 1974/4885ABCB11 29/4885 |
| US-20070065444-A1 | Human monoclonal antibodies to activin receptor-like kinase-1 | SMAD3, SMAD2, ACVR1 | PTGS2 4769/4885PTGS1 4487/4885ABCB11 4469/4885 |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | PTGS2 3101/4885PTGS1 2342/4885ABCB11 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.